SCYX Scynexis Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SCYX

Price (delayed)

$5.22

Market cap

$51.94M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.09

Enterprise value

$43.21M

?
Relative Growth: Rel. Growth: 68
Relative Strength: Rel. Strength: 32
Relative Valuation: Rel. Valuation: 16
Relative Profitability: Rel. Profitability: 44

SCYNEXIS, Inc. is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS is developing the company’s ...

Highlights
Scynexis's quick ratio has surged by 149% QoQ and by 84% YoY
Scynexis's debt has plunged by 81% from the previous quarter and by 19% YoY
Scynexis's revenue has decreased by 6% QoQ
The gross profit is down by 6% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.scynexis.com

Key stats

What are the main financial stats of SCYX

SCYX stock price

How has the Scynexis stock price performed over time
Intraday
0.97%
1 week
-7.94%
1 month
7.85%
1 year
-21.86%
YTD
3.16%
QTD
28.26%

Financial performance

How have Scynexis's revenue and profit performed over time
Revenue
$19.22M
Gross profit
$19.22M
Operating income
-$22.6M
Net income
-$10.24M
Gross margin
100%
Net margin
-53.3%
Scynexis's net margin has soared by 91% YoY and by 56% from the previous quarter
The operating margin has soared by 90% YoY
The company's net income has surged by 58% QoQ and by 48% YoY
SCYX's operating income is up by 38% YoY and by 7% QoQ

Price vs fundamentals

How does SCYX's price correlate with its fundamentals

Growth

What is Scynexis's growth rate over time

Valuation

What is Scynexis stock price valuation
P/E
N/A
P/B
0.77
P/S
3.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.25
The company's EPS rose by 45% QoQ and by 34% YoY
SCYX's price to book (P/B) is 65% lower than its 5-year quarterly average of 2.2 and 3.8% lower than its last 4 quarters average of 0.8
The equity has surged by 62% since the previous quarter and by 51% year-on-year
The P/S is 76% lower than the 5-year quarterly average of 13.5 and 34% lower than the last 4 quarters average of 4.9
Scynexis's revenue has decreased by 6% QoQ

Efficiency

How efficient is Scynexis business performance
The company's return on sales has surged by 91% YoY and by 56% QoQ
The return on equity has surged by 63% since the previous quarter and by 44% year-on-year
SCYX's return on invested capital has surged by 63% since the previous quarter and by 26% year-on-year
Scynexis's return on assets has surged by 61% QoQ and by 36% YoY

Dividends

What is SCYX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SCYX.

Financial health

How did Scynexis financials performed over time
Scynexis's quick ratio has surged by 149% QoQ and by 84% YoY
The current ratio has soared by 145% from the previous quarter and by 86% YoY
Scynexis's debt is 97% less than its equity
The company's debt to equity has shrunk by 88% QoQ and by 40% YoY
Scynexis's debt has plunged by 81% from the previous quarter and by 19% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.